Nautilus Biotechnology, Inc. Earnings Per Share Disclosure
| (in thousands, except share and per share data) | Year Ended December 31, 2025 | Year Ended December 31, 2024 | |||||||||
| Numerator: | |||||||||||
| Net loss attributable to common stockholders | $ | (59,001) | $ | (70,780) | |||||||
| Denominator: | |||||||||||
| Weighted average shares used in computing net loss per share attributable to common stockholders, basic and diluted | 126,256,583 | 125,426,509 | |||||||||
| Net loss per share attributable to common stockholders, basic and diluted: | $ | (0.47) | $ | (0.56) | |||||||
| Year Ended December 31, 2025 | Year Ended December 31, 2024 | ||||||||||
| Options to purchase common stock | 17,270,870 | 16,634,775 | |||||||||
| Employee stock purchase plan | 92,350 | 144,928 | |||||||||
| Total potentially dilutive common share equivalents | 17,363,220 | 16,779,703 | |||||||||
Want the next Nautilus Biotechnology, Inc. earnings per share disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment Nautilus Biotechnology, Inc.'s next filing hits EDGAR. No credit card, your email never gets sold.
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.